1. Home
  2. EVO

as of 10-01-2026 3:37pm EST

$1.66
$0.05
-2.92%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Founded: 1993 Country:
Germany
Germany
Employees: N/A City: N/A
Market Cap: 568.6M IPO Year: 2007
Target Price: $4.17 AVG Volume (30 days): 153.5K
Analyst Decision: Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $1.50 - $4.27 Next Earning Date: 11-05-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): -23.78% Revenue Growth (next year): 20.51%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Share on Social Networks: